Protocols for vaccination and prophylactic antibiotics to reduce the risk of meningococcal infection and dosing of eculizumab are identical to those recommended for treatment of atypical HUS.
Approval is for a 4 month treatment course.
After this the expert panel will review clinical data with the referring clinical team to determine treatment outcome.
If there is loss of the graft function despite treatment, or if there is ongoing deterioration in graft function (eGFR) with no evidence of response to treatment, eculizumab is withdrawn.
If there is stabilisation of graft function (eGFR) or an improvement in graft function (eGFR), eculizumab is withdrawn, but may be reintroduced if there is subsequent deterioration in graft function and the initial starting eligibility criteria are fulfilled.